Is the First Postnatal Platelet Mass as an Indicator of Patent Ductus Arteriosus?


Journal

Archives of Iranian medicine
ISSN: 1735-3947
Titre abrégé: Arch Iran Med
Pays: Iran
ID NLM: 100889644

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 24 09 2018
accepted: 07 07 2019
entrez: 12 12 2019
pubmed: 12 12 2019
medline: 25 9 2020
Statut: epublish

Résumé

The aim of this study is to evaluate whether there is an association between the platelet mass and patent ductus arteriosus (PDA) closure in premature newborns. Preterm infants (gestational age ≤33 weeks) with hemodynamically significant PDA (group 1, n = 178) and a control group of preterm infants without PDA (group 2, n = 211) were retrospectively evaluated between August 1, 2013 and July 30, 2015 in the neonatal intensive care unit (NICU). Platelet counts and platelet indices including mean platelet volume (MPV), and platelet mass (platelet count x mean platelet volume) in the first 24 hours of life, demographic findings and morbidities were recorded. No differences were observed in demographic findings between the study groups in terms of birth weight, gestational age, gender and maternal risk factors. The mean platelet count in the first postnatal hemogram in group 1 and group 2 were 189.43 ± 72.14 (X103 /mm3) and 206.86 ± 70.11(X103/mm3), respectively (P < 0.05). The MPV were similar in both groups (P > 0.05). Platelet mass values were 1443.70 ± 572.40 fL/nL in Group 1 and 1669.49 ± 1200.42 fL/nL in group 2. There was a statistically significant difference in platelet mass values between the two groups (P = 0.011). Multivariable analysis including presence of thrombocytopenia, MPV and platelet mass showed that hemodynamically significant PDA was not independently associated with platelet count <150 000 (OR = 1.001, 95% CI 0.980-1.023; P = 0.921), MPV (OR = 0.967, 95% CI 0.587-1.596; P = 0.897) or platelet mass (OR = 0.999, 95% CI 0.997-1.002; P = 0.681). The optimal cut-off value of platelet mass for patients with PDA was ≤1530.8 fL/nL (area under the curve [AUC]: 0.580), with sensitivity of 58% and specificity of 56.2% (P = 0.008). Our data suggest that platelet count, MPV, and platelet mass do not contribute to closure of PDA in premature newborns.

Sections du résumé

BACKGROUND
The aim of this study is to evaluate whether there is an association between the platelet mass and patent ductus arteriosus (PDA) closure in premature newborns.
METHODS
Preterm infants (gestational age ≤33 weeks) with hemodynamically significant PDA (group 1, n = 178) and a control group of preterm infants without PDA (group 2, n = 211) were retrospectively evaluated between August 1, 2013 and July 30, 2015 in the neonatal intensive care unit (NICU). Platelet counts and platelet indices including mean platelet volume (MPV), and platelet mass (platelet count x mean platelet volume) in the first 24 hours of life, demographic findings and morbidities were recorded.
RESULTS
No differences were observed in demographic findings between the study groups in terms of birth weight, gestational age, gender and maternal risk factors. The mean platelet count in the first postnatal hemogram in group 1 and group 2 were 189.43 ± 72.14 (X103 /mm3) and 206.86 ± 70.11(X103/mm3), respectively (P < 0.05). The MPV were similar in both groups (P > 0.05). Platelet mass values were 1443.70 ± 572.40 fL/nL in Group 1 and 1669.49 ± 1200.42 fL/nL in group 2. There was a statistically significant difference in platelet mass values between the two groups (P = 0.011). Multivariable analysis including presence of thrombocytopenia, MPV and platelet mass showed that hemodynamically significant PDA was not independently associated with platelet count <150 000 (OR = 1.001, 95% CI 0.980-1.023; P = 0.921), MPV (OR = 0.967, 95% CI 0.587-1.596; P = 0.897) or platelet mass (OR = 0.999, 95% CI 0.997-1.002; P = 0.681). The optimal cut-off value of platelet mass for patients with PDA was ≤1530.8 fL/nL (area under the curve [AUC]: 0.580), with sensitivity of 58% and specificity of 56.2% (P = 0.008).
CONCLUSION
Our data suggest that platelet count, MPV, and platelet mass do not contribute to closure of PDA in premature newborns.

Identifiants

pubmed: 31823619
pii: S1029-2977-22(12)687-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

687-691

Informations de copyright

© 2019 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Auteurs

Selahattin Akar (S)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Sevilay Topcuoglu (S)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Abdulhamid Tuten (A)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Elif Ozalkaya (E)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Hande Ozgun Karatepe (HO)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Tulin Gokmen (T)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Fahri Ovali (F)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Guner Karatekin (G)

Division of Neonatology, Department of Pediatrics, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH